Annovis Bio, Inc.ANVSNYSE
Loading
Operating Expenses Over TimeExpanding
Percentile Rank88
3Y CAGR+5.2%
5Y CAGR+34.9%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+5.2%/yr
vs +144.5%/yr prior
5Y CAGR
+34.9%/yr
Recent deceleration
Acceleration
-139.3pp
Decelerating
Percentile
P88
Within normal range
vs 5Y Ago
4.5x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$29.70M+11.2%
2024$26.69M-40.7%
2023$45.03M+76.5%
2022$25.51M+75.5%
2021$14.54M+118.9%
2020$6.64M+313.5%
2019$1.61M+124.9%
2018$713937.00+4.6%
2017$682433.00-